Lupin Ltd., a leading pharmaceutical player, has announced the commercial launch of its generic Tolvaptan tablets in the United States, targeting patients with autosomal dominant polycystic kidney disease (ADPKD). Following a regulatory nod from the U.S. Food and Drug Administration (USFDA), Lupin now holds the coveted 180-day exclusivity window for this therapy, positioning the company advantageously in a high-value therapeutic segment.